Biopharmaceutical company UCB has entered a divestment agreement in China to sell, divest and license its mature neurology and allergy business to CBC Group and Mubadala in a deal valued at $680m.
The neurology portfolio includes Keppra, Vimpat and Neupro and the allergy portfolio comprises Zyrtec and Xyzal.
UCB is also divesting its Zhuhai manufacturing site.
CBC Group is an Asian healthcare-focused asset management group. Mubadala is an investment company based in the United Arab Emirates.
By divesting its mature business in China, UCB aims to re-align its operations with the dynamic needs of the Chinese pharmaceutical market.
The strategic move will enable the company to concentrate on areas of innovation and foster partnerships, ensuring alignment with its long-term strategic objectives in the region.
In 2023, the combined net sales of mature business assets in China reached €131m.
The deal will conclude in the fourth quarter (Q4) of 2024.
The agreement will not affect UCB’s financial guidance for 2024. However, subject to the deal’s closure, a marginal dilution of the adjusted earnings before interest, taxation, depreciation and amortisation (EBITDA) margin is expected for 2025.
The company maintains its adjusted EBITDA margin forecast for 2025 at the low end of the low-to-mid-30s percentage range of revenue.
Lazard is serving as financial advisor to UCB for this transaction, with Freshfields Bruckhaus Deringer providing legal counsel.
CBC Group and Mubadala have appointed PJT Partners as their financial advisor and Clifford Chance as their legal advisor.
UCB CEO Jean-Christophe Tellier stated: “In the short term, UCB is exploring the launch of novel medicines in immunology, neurology and rare diseases in China.
“Our dedication to serving patients with unmet needs in China remains steadfast. Building on our 28-year presence in the country, we are committed to driving patient outcomes through continued collaboration with local partners and fostering innovation.”
In October 2023, the US Food and Drug Administration (FDA) approved UCB’s BIMZELX (bimekizumab) to treat moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
Source: pharmaceutical-technology.com
Pharma and medical imaging company MedTrace announced the appointment of Nicholas Borys, M.D., as Chief Medical Officer (CMO). Dr. Borys is a skilled and experienced healthcare executive with over 25 years experience in advancing portfolios of novel therapies across diverse indications in cardiovascular, cancer, and central nervous system disease.
Eli Lilly and Company has announced a significant expansion of its manufacturing presence in Ireland, with a $1bn investment earmarked for its Limerick site. The move is aimed at boosting the company’s production of biologic active ingredients, including those for its approved Alzheimer’s treatment.
Lonza recently announced that it has completed a planned expansion of the mid-scale microbial manufacturing facility at its Visp, Switzerland site. This multi-product facility was recently granted a GMP license, allowing cGMP manufacturing and release of biologics produced using microbial fermentation.
